Researchers have identified a protein, TMEM16F, that appears to aid the spread of Parkinson’s pathology in the brain.

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

The following column was originally published on Feb. 25, 2022. Thanks to breakthroughs in medicine and nutrition in recent years, we are living longer than ever before. But this increase in life ...

In the United States, out-of-pocket (OOP) costs of brand-name medications for neurological ... and 45,909 with Parkinson’s ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Early initiation of pimavanserin among patients with Parkinson disease psychosis were more likely to experience complete symptom resolution.

Research led by the University of Michigan has provided compelling evidence that could solve a fundamental mystery in the makeup of fibrils that play a role in Alzheimer's, Parkinson's and other ...

A person battling multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, but by 202 ...

A large trial showed that semaglutide, sold as Ozempic for diabetes and as Wegovy for obesity, was better than any current ...

The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), ...

Geroscience has a long way to go, but there are four FDA-approved drugs that have shown promise to “target the process of ...